Compare SCOR & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCOR | IPHA |
|---|---|---|
| Founded | 1999 | 1999 |
| Country | United States | France |
| Employees | N/A | 163 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.4M | 131.4M |
| IPO Year | 2007 | N/A |
| Metric | SCOR | IPHA |
|---|---|---|
| Price | $7.31 | $1.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.75 |
| AVG Volume (30 Days) | 12.7K | ★ 22.6K |
| Earning Date | 05-05-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 127.37 | N/A |
| EPS | ★ 4.25 | N/A |
| Revenue | ★ $403,549,000.00 | N/A |
| Revenue This Year | $2.75 | $180.36 |
| Revenue Next Year | $7.30 | N/A |
| P/E Ratio | $1.73 | ★ N/A |
| Revenue Growth | ★ 1.02 | N/A |
| 52 Week Low | $4.39 | $1.18 |
| 52 Week High | $10.18 | $2.63 |
| Indicator | SCOR | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 44.36 | 45.03 |
| Support Level | $6.28 | $1.35 |
| Resistance Level | $7.18 | $1.80 |
| Average True Range (ATR) | 0.54 | 0.08 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 16.35 | 10.00 |
comScore Inc is a information and analytics company that measures advertising, content, and the consumer audiences of each, across media platforms. It create products using a data platform that combines information on digital platforms (connected televisions, mobile devices, tablets and computers), televisions, direct to consumer applications, and movie screens with demographics and other descriptive information. The company has developed proprietary data science that enables measurement of person-level and household-level audiences, removing duplicated viewing across devices and over time. Its segments include Content & Ad Measurement and Research & Insight Solutions of which the Content & Ad Measurement segment derives the majority of the revenue.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.